IL204850A0 - Cytomegalovirus vaccines and methods of production - Google Patents

Cytomegalovirus vaccines and methods of production

Info

Publication number
IL204850A0
IL204850A0 IL204850A IL20485010A IL204850A0 IL 204850 A0 IL204850 A0 IL 204850A0 IL 204850 A IL204850 A IL 204850A IL 20485010 A IL20485010 A IL 20485010A IL 204850 A0 IL204850 A0 IL 204850A0
Authority
IL
Israel
Prior art keywords
production
methods
cytomegalovirus vaccines
cytomegalovirus
vaccines
Prior art date
Application number
IL204850A
Other languages
English (en)
Original Assignee
Univ Princeton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton filed Critical Univ Princeton
Publication of IL204850A0 publication Critical patent/IL204850A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16164—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL204850A 2007-10-10 2010-04-06 Cytomegalovirus vaccines and methods of production IL204850A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99842607P 2007-10-10 2007-10-10
PCT/US2008/079494 WO2009049138A1 (en) 2007-10-10 2008-10-10 Cytomegalovirus vaccines and methods of production

Publications (1)

Publication Number Publication Date
IL204850A0 true IL204850A0 (en) 2010-11-30

Family

ID=40549581

Family Applications (1)

Application Number Title Priority Date Filing Date
IL204850A IL204850A0 (en) 2007-10-10 2010-04-06 Cytomegalovirus vaccines and methods of production

Country Status (15)

Country Link
US (2) US9439960B2 (enExample)
EP (1) EP2200645B1 (enExample)
JP (1) JP5409638B2 (enExample)
KR (1) KR20100084627A (enExample)
CN (1) CN101820906B (enExample)
AU (1) AU2008310713B2 (enExample)
BR (1) BRPI0818656A2 (enExample)
CA (1) CA2701727C (enExample)
IL (1) IL204850A0 (enExample)
MX (1) MX2010003713A (enExample)
NZ (1) NZ584459A (enExample)
RU (1) RU2491340C2 (enExample)
SG (1) SG185291A1 (enExample)
WO (1) WO2009049138A1 (enExample)
ZA (1) ZA201002216B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
TWI570240B (zh) 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP2831285B1 (en) * 2012-03-27 2019-10-30 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
MX378747B (es) 2012-07-06 2025-03-10 Glaxosmithkline Biologicals S A Star Complejos de proteínas de citomegalovirus.
AU2013293570B2 (en) 2012-07-27 2019-05-23 City Of Hope An MVA vaccine for delivery of a UL128 complex and preventing CMV infection
US9395369B2 (en) 2012-10-19 2016-07-19 Regents Of The University Of Minnesota Guinea pig cytomegalovirus (CIDMTR strain)
CN103937871B (zh) * 2013-01-23 2019-07-23 上海市东方医院 Srrp35基因和表达产物在癌症诊断与治疗中的应用
US20160289303A1 (en) * 2013-11-15 2016-10-06 President And Fellows Of Harvard College Methods and compositions for the treatment of hcmv
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3601543A4 (en) * 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS
CA3060019A1 (en) * 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
WO2019089410A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
US4058598A (en) 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
US6471965B1 (en) 1994-07-27 2002-10-29 Bio-Virus Research Incorporated Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2005012545A2 (en) 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production

Also Published As

Publication number Publication date
RU2491340C2 (ru) 2013-08-27
US20170014504A1 (en) 2017-01-19
AU2008310713B2 (en) 2012-06-14
KR20100084627A (ko) 2010-07-27
BRPI0818656A2 (pt) 2015-04-14
EP2200645A4 (en) 2012-07-11
JP2011500592A (ja) 2011-01-06
CN101820906A (zh) 2010-09-01
EP2200645A1 (en) 2010-06-30
CA2701727C (en) 2016-12-13
CN101820906B (zh) 2015-04-22
US10300130B2 (en) 2019-05-28
NZ584459A (en) 2012-06-29
MX2010003713A (es) 2010-08-02
US9439960B2 (en) 2016-09-13
US20100285059A1 (en) 2010-11-11
WO2009049138A1 (en) 2009-04-16
ZA201002216B (en) 2011-06-29
SG185291A1 (en) 2012-11-29
JP5409638B2 (ja) 2014-02-05
CA2701727A1 (en) 2009-04-16
AU2008310713A1 (en) 2009-04-16
RU2010117741A (ru) 2011-11-20
EP2200645B1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
IL204850A0 (en) Cytomegalovirus vaccines and methods of production
EG27167A (en) Microemulsifiers and methods of making and using same
EP2398494A4 (en) Proproteins and their methods of use
IL217745A0 (en) Antiviral compounds and methods of making and using thereof
ZA200905626B (en) Adjuvants and methods of using them
SI2516468T1 (sl) Protitelesa proti flt3 in postopki uporabe istih
ZA201107555B (en) Anti-17f antibodies and methods of use thereof
IL252490A0 (en) Ceramic-ceramic bonding and related methods
EP2464227A4 (en) COMPOUNDS AND METHODS OF USE
IL236830A0 (en) Diazahomoredene derivatives and methods of using them
GB0910725D0 (en) Mutant proteins and methods for producing them
EP2444398A4 (en) NEW INTERMEDIATE PRODUCTS FROM VORICONAZOLE AND PRODUCTION PROCESS FOR VORICONAZOLE THEREWITH
EP2512309A4 (en) GRID AND METHOD OF USE
PL2243725T3 (pl) Element opakowaniowy i sposób jego wytwarzania
SG10201405757RA (en) Coupling devices and methods of using them
SI2557084T1 (sl) Kalcijev rosuvastatin polizdelek in postopek za njegovo pripravo
EP2212251A4 (en) PROCESS FOR THE PRODUCTION OF CLUSTERBOR
ZA201204347B (en) New tertiary 8-hydroxyquinoline-7-carboxamide derivatives and uses thereof
IL229968A0 (en) Tetrazolyloxy derivatives and methods for their production
ZA201204133B (en) Health-beneficial preparation and production method
GB201115521D0 (en) Colorant-polyesters and methods of producing colorant-polyesters
GB0714290D0 (en) Product and method of manufacture
EP2649217A4 (en) ARTICLE AND METHOD FOR ITS MANUFACTURE AND USE
EP2205524A4 (en) METHODS OF MANUFACTURING CLUSTER BORON
EP2205525A4 (en) PROCESS FOR THE PREPARATION OF CLUSTERBORON